XE

Xeno Transplants CorpOOTC XENO Stock Report

Last reporting period 31 Mar, 2008

Updated 02 Aug, 2023

Last price

Market cap $B

Exchange

OOTC - OTC

XENO Stock Analysis

XE

Uncovered

Xeno Transplants Corp is uncovered by Eyestock quantitative analysis.

Market cap $B

Dividend yield

Shares outstanding

40.36 B

Website

Xeno Transplants Corporation, formerly Icon Development, Inc., is a bio-technology research and development company that holds an exclusive commercial license from Massachusetts General Hospital derived from over 15 years of development in the field of xenotransplantation by Novartis Pharmaceuticals and its associated research entities. The Company intends to develop therapeutic applications of organs and cells derived from genetically engineered pigs as a transplant alternative to limited human donor sources.

View Section: Eyestock Rating